Genmab A/S annual net income
2021
2022
2023
2024
2025
Genmab A/S Net Income Growth & History (GMAB)
Genmab A/S's net income was $963.0M for fiscal 2025.
View full Genmab A/S company overviewGenmab A/S annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $963.0M | −$170.0M | −15.00% |
| 2024 | 2024-12-31 | $1.13B | $502.0M | +79.56% |
| 2023 | 2023-12-31 | $631.0M | −$153.7M | −19.59% |
| 2022 | 2022-12-31 | $784.7M | $334.5M | +74.31% |
| 2021 | 2021-12-31 | $450.2M | — | — |
Genmab A/S quarterly net income
Q2.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $303.0M | −$33.0M | −9.82% |
| Q1 2026 | 2026-03-31 | $53.0M | — | — |
| Q4 2025 | 2025-12-31 | $31.0M | — | — |
| Q3 2025 | 2025-09-30 | $401.0M | — | — |
| Q2 2025 | 2025-06-30 | $336.0M | $133.0M | +65.52% |
| Q2 2024 | 2024-06-30 | $203.0M | — | — |
Genmab A/S net income trends
Between the periods ended 2021-12-31 and 2025-12-31, Genmab A/S's net income increased from $450.2M to $963.0M, a change of $512.8M. The latest reported quarter, Q2 2026, shows $303.0M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Genmab A/S source filings ↗Community posts
Genmab reports mature survival data for petosemtamab in head and neck cancer
Genmab ($GMAB) reported median overall survival of 28.2 months with petosemtamab plus pembrolizumab in a Phase 2 study of previously untreated, recurrent or metastatic PD-L1-positive head and neck cancer. Among 43 patients evaluable for eff ...
Genmab and Incyte agree colorectal-cancer combination trial
Genmab ($GMAB) and Incyte ($INCY) agreed to test a three-part treatment approach in previously untreated metastatic colorectal cancer carrying a KRAS G12D mutation. The planned Phase 1/2 study combines Genmab’s petosemtamab, an antibody tar ...
